Emerging Therapies for the Management of Castration - Sensitive Prostate Cancer

 This webinar is open to the public. You do not need to be an ACCC member to view this webinar, but you will need to create an account in order to register.  

 If You DO NOT Have an ACCC Account: 

  • To start, click the green “Register” button in the upper right corner of this page. You will be directed to “Your Cart.” Click the green “Log In” button near the top of the page. 
  • ACCC and State Society Members: Click “Reset Password” to update your login information. When your password is updated, you will be redirected to the “My Profile” page.  
  • Non-members: Click “Create Account.” Once your password is created, you will be redirected to the "My Profile" page.  
  • Click “eLearning” at the top of your profile page to go back to the ACCC eLearning portal. In the box on the left side of the screen, click on the “Cart” link. 
  • The green box in the upper right corner of this page will indicate “You are registered!” for this course! 

If You Have an ACCC Account: 

  • Please click the orange “Log In” button on the left side of this screen. You will be taken to the main login page that displays your email and password. Click the “Log in” button. 
  • You will be automatically redirected back to webinar page, and the green box in the upper right corner will say that “You are registered!” for this course! 

PRO TIP: If you save your ACCC password to your computer and remain logged in, you can register for additional webinars and courses in a matter of seconds—with just one click!  

For the best registration and viewing experience, please use Chrome, Edge, or Safari web browsers. Internet Explorer Users may experience difficulties accessing the webinar. 

Once you complete your registration, you will receive an email from ACCC eLearning, which contains information on how to access this webinar. For assistance with registration or if you do not receive an email, please contact registration@accc-cancer.org.

Release Date: January 29, 2021
Expiration Date: January 28, 2022

Estimated time to complete:  60 minutes

This educational activity is jointly provided by AXIS Medical Education and the Association of Community Cancer Centers (ACCC).

This activity is supported by an educational grant from Astellas and Pfizer, Inc.

Target Audience

The target audience for this initiative includes medical oncologists, urologic oncologists, urologists, oncology advanced practice providers (nurse practitioners, physician assistants), oncology pharmacists, oncology nurses, and other healthcare professionals (HCPs) involved in treating patients with prostate cancer.  


Prostate cancer is the second most common cancer, after skin cancer, among men. It is the second leading cause of cancer death in the United States. This year, it is estimated that about 174,650 men in the United States will be diagnosed with prostate cancer and 31,620 men will die from this disease. Androgen deprivation therapy (ADT) aimed at lowering the level of androgens, is the standard of care for men with advanced prostate cancer. Newly diagnosed metastatic disease that has spread to other parts of the body and still responds to testosterone suppression therapy is called metastatic castration-sensitive prostate cancer (mCSPC). Androgen receptor inhibitors are currently being investigated in combination with ADT given the knowledge that deeper androgen signal inhibition results in further improved outcomes in mCSPC. With the recent drug approvals and updates to clinical practice guidelines, several knowledge, competence and performance gaps exist in the optimal management of mCSPC among oncology practitioners. Participants from previous Association of Community Cancer Centers (ACCC) educational programs revealed transitions of care, including communication between the numerous healthcare settings (52%), side effect management (45%), and keeping current on the latest treatment modalities (29%) as among the most commonly encountered challenges for practitioners.  

This education activity will provide guidance on the optimal management of mCSPC to oncologists, urologists, oncology advanced practitioners and other members of the multidisciplinary cancer care team. The educational program will address some of the challenges in optimal sequencing of care in mCSPC and will provide an opportunity to discuss with leading oncology experts and colleagues how new research clinical updates can be translated into new patient care strategies.  


At the end of this educational activity, participants should be able to:

Describe current and emerging treatment options in mCSPC.  

Employ strategies for optimal management of treatment-related adverse events experienced by patients treated for mCSPC.  

Examine solutions for improving coordination and communication within the multidisciplinary cancer care team and with patients/caregivers to improve outcomes for patients with mCSPC . 


Archana Ajmera, MSN, ANP-BC, AOCNP
Advance Practice Provider Supervisor
Division of Hematology/Oncology
UCSD Moores Cancer Center    

Pedro Barata, MD, MSc
Assistant Professor
Deming Department of Medicine
Division of Hematology/Oncology
Genitourinary Cancers
Tulane University 

Erik Castle, MD, FACS
Professor of Urology 
Tulane University

Lisa M. Holle, PharmD, BCOP, FHOPA, FISOPP 
Associate Clinical Professor of Pharmacy Practice

Department of Pharmacy Practice
UConn School of Medicine


Accreditation Statement

Jointly Accredited Provider Logo

In support of improving patient care, this activity has been planned and implemented by AXIS Medical Education and Association of Community Cancer Centers (ACCC). AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Credit Designation for Physicians

AXIS Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation for Pharmacists

This application-based activity is approved for 1.0 contact hours of continuing pharmacy education credit JA4008106-9999-21-029-H01-P.

Credit Designation for Nursing

AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hours.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

AXIS Contact Information

For information about the accreditation of this program please contact AXIS at info@axismeded.org.

Disclosure of Conflicts of Interest

AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, reviewers and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies. An ineligible entity is any organization whose primary business is t producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest are identified and mitigated prior to initiation of the planning phase for an activity.   

AXIS has mitigated and disclosed to learners all relevant conflicts of interest disclosed by  staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.  

 The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months: 

Name of Faculty or Presenter/Planner

Reported Financial Relationship

Archana Ajmera, MSN, ANP-BC, AOCNP 

Nothing to disclose 

Pedro Barata, MD, MSc 

Consultant: Astellas; Eisai; EMD Serono; Dendreon; Pfizer, Inc.: and Seattle Genetics.  Contracted Research: AstraZeneca.   Research GrantBlueEarth Diagnostics Speaker’s Bureau: Bayer and Caris. 

Erik Castle, MD, FACS 

Nothing to disclose 

Lisa Holle, PharmD, BCOP, FHOPA, FISOPP

Nothing to disclose 

The directors, planners, managers and reviewers reported the following financial relationships they have with any ineligible company of any amount during the past 24 months:  

Name of Planner/Manager/Reviewer

Reported Financial Relationship

Leigh M. Boehmer, PharmD, BCOP

Nothing to disclose

Eric Castle, MD 

Nothing to disclose

Lisa M Holle, PharmD, BCOP, FHOPA 

Nothing to disclose

Marilyn Haas, PhD, RN, CNS, ANP-BC

Nothing to disclose

Dee Morgillo, MEd., MT(ASCP), CHCP

Nothing to disclose

Latha Shivakumar, PhD, CHCP 

Nothing to disclose


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

System Requirements

For the best registration and viewing experience, please use Chrome, Edge, or Safari web browsers. Internet Explorer users may experience difficulties accessing the sessions. 

Method of Participation and Request for Credit      

To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.

Archana Ajmera, MSN, ANP-BC-AOCNP

Advanced Practice Provider Supervisor, Division of Hematology/Oncology

UCSD Moores Cancer Center

Archana Ajmera, MSN, is a board-certified adult nurse practitioner (ANP-BC) and an advanced oncology certified nurse practitioner (AOCNP). She is currently working as an NP at UC San Diego Health Moores Cancer Center and helps treat people with prostate cancer, renal cell carcinoma, urothelial carcinoma, testicular germ cell tumors and penile carcinoma. Her scope of practice includes collaborating with her physician colleagues in physical evaluations, diagnosis, treatment, symptom management, supportive care, and end of life care. Additionally, she is currently the Advanced Practice Provider Supervisor of Moores Cancer Center at UCSD Health. 
Mrs. Ajmera is also a board-certified women’s health care nurse practitioner (WHNP-BC). She obtained a master’s degree in nursing from Massachusetts General Hospital Institute of Health Professions School of Nursing in Boston. She earned her bachelor’s degree in nutritional science from UC Berkeley. She is a member of the American Society of Clinical Oncology and National Comprehensive Cancer Network (NCCN).  

Pedro C. Barata, MD, MSc

Assistant Professor of Medicine Hematology & Medical Oncology, Tulane University

Dr. Pedro Barata earned his medical degree from the New University of Lisbon in 2009 and completed his medical oncology training in 2016. Subsequently, he was invited to join the genitourinary group at Taussig Cancer Center, where he worked as a clinical fellow in genitourinary malignancies. Dr. Barata then moved to Tulane University to continue his clinical and research work in the GU field. Dr. Barata successfully expanded the genitourinary program offered at Tulane Cancer Center and he currently leads the kidney and bladder cancer program at Tulane University with a focus on clinical trials.  

 Dr. Barata has authored or co-authored more than 60 research publications in high-quality journals, such as Cancer, Annals of Oncology, and CA: Cancer journal Clinicians, with more than 700 scientific citations. He has presented multiple abstracts at important national and international meetings and has won multiple prestigious awards, including the Scholar-in-Training Award, AACR-NCI-EORTC Triple Meeting (2017) and the Annual Accelerating Anticancer Agent Development and Validation (AAADV) Program Scholarship (2018). He serves as a reviewer for prestigious peer-reviewed journals, such as JAMA Oncology, ASCO and Journal Global Oncology. 

Erik Castle, MD, FACS

Professor of Urology

Tulane University, New Orleans, LA

Dr. Erik Castle is a Professor of Urology at Tulane University School of Medicine, specializing in urologic oncology surgery and minimally invasive/robotic surgery.  

Dr. Castle's surgical expertise includes robot-assisted radical cystectomy, prostatectomy, retroperitoneal lymph node dissection, and partial nephrectomy. He pioneered robot-assisted radical cystecomy in 2005 and robot-assisted RPLND in 2008 being one of the first surgeons in the world performing these surgeries at that time. Dr. Castle has demonstrated many of these procedures internationally and has published extensively across topics of urologic care and science. He serves on the Early Detection of Prostate Cancer Panel for the National Comprehensive Cancer Network (NCCN).  

He earned his medical degree from University of Texas, Southwestern Medical School. He completed Urology Residency at the University of Kansas Medical Center and followed with a Laparoscopic and Reconstructive Urologic Surgery fellowship at Mayo Clinic of Arizona. Dr. Castle's research focus includes prostate, bladder, testicular, and kidney cancers. He has experience in clinical trials, health sciences research, outcomes research, and basic science research. 

Lisa M. Holle, PharmD, BCOP, FHOPA, FISOPP

Associate Clinical Professor of Pharmacy Practice, Department of Pharmacy Practice, UConn School of Medicine

Dr. Holle completed her Bachelor of Science in Pharmacy and post-baccalaureate Doctor of Pharmacy from the University of Wisconsin–Madison. She completed a specialized oncology residency at UT M.D. Anderson Cancer Center, and is a board-certified oncology pharmacist. Dr. Holle has worked as an oncology pharmacist for over 20 years in a variety of settings including private hospitals, academic medical centers, and medical communications. Currently, Dr. Holle is an Associate Clinical Professor at the UConn School of Pharmacy and Associate Professor at the UConn School of Medicine. Her practice site is at the UConn Health Carole and Ray Neag Comprehensive Cancer Center, where she works in a team-based ambulatory care clinic focusing on genitourinary and gastrointestinal cancers and in another team based-clinic focusing on hematologic malignancies.  

Dr. Holle is a Past President of HOPA and a past Secretariat member and Treasurer of the International Society of Oncology Pharmacy Practitioners (ISOPP). She is also an active member in many other professional oncology and pharmacy organizations. Dr. Holle’s clinical research program focuses on numeracy and patient decision-making, oncology quality improvement initiatives, medical marijuana, and oral anticancer therapy management.  


4 Questions
Course Content
Recorded 01/15/2021
Recorded 01/15/2021 After viewing the lecture, please complete the post assessment and the course evaluation to receive CE credit
Post-activity Assessment
4 Questions  |  3 attempts  |  9/12 points to pass
4 Questions  |  3 attempts  |  9/12 points to pass
Course Evaluation
15 Questions
15 Questions This evaluation must be completed to receive credit for this course. Estimated time to complete is 5 minutes.
CME/CPE/CNE/Certificate of Participation
Up to 1.00 medical credits available  |  Certificate available
Up to 1.00 medical credits available  |  Certificate available Please note: If you have completed a course prior to May 2020 and need a copy of your CME or CNE certificate, please email rburtnick@accc-cancer.org and include your full name, credentials, and email address.